Over the past decade, open access publishing has exploded. On its surface, this has been framed as an unambiguous good: more access, more dissemination, more democratization of knowledge. But beneath that narrative lies a more uncomfortable question that deserves honest scrutiny: What happens to scientific rigor when publishing becomes a pay-to-play enterprise?
I did not arrive at this question as an outsider. My early research training as an NIH fellow during the COVID-19 pandemic instilled in me a very clear ethos: Scientific literature is a shared public good, and its integrity is nonnegotiable. Methodological rigor was not treated as academic nitpicking. It was treated as a moral obligation tied directly to patient care. That mindset carried forward into medical school, where I became increasingly involved in writing letters to the editor addressing unaccounted for confounding, flawed statistical methods, and, in some cases, outright invalid study designs. These were not attempts to be contrarian. They were attempts to correct the record.
What I did not anticipate was that correcting the scientific record would come with a price tag.
Many exclusively open access journals charge authors thousands of dollars to publish original research, sometimes more than $6,000. That much is well known. What is discussed far less is that some of these same journals will charge additional fees, often approaching or exceeding $1,500, to publish letters to the editor that identify serious methodological flaws in previously published work. I have personally encountered this barrier. In multiple instances, when attempting to submit short correspondences outlining clear issues, such as duplicated patient populations in meta-analyses — a fundamental violation of basic research principles — I was required to pay substantial article processing charges. Requests for fee waivers were denied. In those moments, the message was unmistakable: The cost of correcting flawed science that made it past the journal’s peer review and editorial scrutiny is an error whose price must be borne by you, not the journal.
This creates an uncomfortable incentive structure. A journal publishes an article and collects several thousand dollars in article processing fees. If that article is later found to contain significant methodological errors, the same journal can collect additional revenue to publish the critique. I am not suggesting that editors are intentionally publishing flawed work to generate downstream income. But it is impossible to ignore that the publication ecosystem, as currently designed, financially rewards journals for publication volume and, in some cases, even the post-publication correction process itself. When the mechanisms for both dissemination and correction are monetized, the appearance of a conflict of interest is unavoidable.
The issue does not stop at post-publication review. It extends into the peer review process itself, which is often described as the backbone of scientific credibility. In reality, peer reviewers are almost universally unpaid. To incentivize participation, many open access publishers now offer discounts on future publication fees, reviewer credits, or public recognition for high-volume reviewers. On paper, this seems reasonable. In practice, it risks shifting the incentive from producing thoughtful, rigorous critiques to simply completing as many reviews as possible. When reviewer “productivity” is measured by quantity rather than quality, the integrity of the process is inevitably compromised. Some journals now publicly highlight their top reviewers in their “Reviewer Hall of Fame” based on volume alone, creating a culture where peer review becomes a competition of output rather than a process grounded in careful, critical evaluation.
Some might argue that the market will self correct, that lower-quality journals will simply be ignored. That is not how the system actually works. Articles published in these venues are PubMed-indexed, searchable, and frequently cited. Once cited, they enter the broader academic ecosystem, where they can be referenced in subsequent studies, systematic reviews, and even clinical guidelines. Over time, flawed or low-quality data can become embedded in the literature, not because it is robust, but because it exists. The veneer of publication becomes a proxy for credibility.
All of this is occurring within a broader publishing landscape dominated by a small number of large, for-profit entities that generate billions of dollars in annual revenue. These companies rely almost entirely on the unpaid labor of the academic community. Researchers design and conduct studies. Peer reviewers evaluate them. Editors curate and oversee the process. And yet the financial rewards flow upward to publishers, not to the individuals who produce and validate the work. It is a system sustained by prestige, not compensation, and one in which participation is effectively mandatory for academic career advancement.
Even those who are not yet fully embedded in academic medicine, such as medical students, are already feeling the downstream effects of this system. In our own national analysis of matched plastic surgery applicants, 68.9% had at least one open access publication prior to applying, and among those who published at all, nearly 80% had done so in an open access journal. The median article processing charge burden per applicant rose to $3,500 in the study’s most recently matched cohort, with more than $2.7 million tied to applicant publications across the study’s three cohorts and some individuals associated with publication portfolios carrying costs approaching $100,000. In effect, participation in the “research arms race” that now defines entry into competitive specialties is increasingly tied not just to productivity, but to financial capacity, underscoring the uncomfortable reality that the pathway into certain fields of medicine may now carry an implicit price for admission.
What makes this dynamic particularly difficult to challenge is that the same publishers that operate open access journals also control many of the most prestigious subscription-based journals in medicine. To speak critically of the system is to risk alienating the very gatekeepers who determine academic progression. As a result, most researchers remain silent, even when they recognize the underlying issues.
I do not pretend to have a simple solution. These are deeply embedded structural issues that will not be resolved by a single policy change or editorial reform. But the first step is acknowledging that the problem exists. Emerging tools, including AI-assisted peer review and community-driven post-publication commentary systems such as those employed by JAMA, may offer new ways to identify errors and improve the reliability of the literature. A model that allows for rapid, transparent, and freely accessible critique, without financial barriers, would be a meaningful step forward.
We must also acknowledge our own role in sustaining this system. As an academic community, we have traded our labor and validation for prestige, reinforcing a model that profits from our participation. If we are serious about reform, we must be willing to critically reassess how we value and cite work published in these venues, reconsider our willingness to provide uncompensated peer review that fuels their growth, and question federal policies that require publicly funded research to be published in public access formats — policies that, in practice, channel taxpayer dollars into article processing charges and shield for-profit publishers from the market pressures that would otherwise constrain these costs.
None of this is to suggest that open access itself is inherently flawed. The ability to freely access scientific research is a meaningful and important advancement. But access without rigor is not progress. If the incentives that govern publication prioritize volume and revenue over methodological quality and post-publication accountability, then the credibility of the entire system that dictates physician decision-making and patient outcomes is at risk. The question is not whether open access publishing has expanded access to science. It clearly has. The question is whether the current incentive structure aligns with the fundamental goal of scientific research — to produce reliable, reproducible knowledge that serves patients. Until we are willing to confront that question directly, the conversation will remain unfinished, and the integrity of the literature will remain, at least in part, an open question.




